Assenagon Asset Management S.A. Has $164 Million Stock Position in Edwards Lifesciences Corporation $EW

Assenagon Asset Management S.A. lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 43.2% during the second quarter, Holdings Channel.com reports. The firm owned 1,812,926 shares of the medical research company’s stock after acquiring an additional 547,212 shares during the period. Assenagon Asset Management S.A.’s holdings in Edwards Lifesciences were worth $163,997,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in EW. Apella Capital LLC increased its position in Edwards Lifesciences by 25.2% in the 2nd quarter. Apella Capital LLC now owns 9,380 shares of the medical research company’s stock valued at $889,000 after buying an additional 1,885 shares in the last quarter. Manitou Investment Management Ltd. raised its stake in Edwards Lifesciences by 2.9% during the 2nd quarter. Manitou Investment Management Ltd. now owns 189,563 shares of the medical research company’s stock worth $17,148,000 after buying an additional 5,368 shares during the period. Orser Capital Management LLC bought a new position in Edwards Lifesciences in the second quarter worth approximately $2,323,000. GAMMA Investing LLC boosted its holdings in Edwards Lifesciences by 12.2% in the second quarter. GAMMA Investing LLC now owns 11,281 shares of the medical research company’s stock worth $1,020,000 after acquiring an additional 1,225 shares in the last quarter. Finally, Versant Capital Management Inc boosted its holdings in Edwards Lifesciences by 79.7% in the second quarter. Versant Capital Management Inc now owns 5,366 shares of the medical research company’s stock worth $485,000 after acquiring an additional 2,380 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the transaction, the vice president owned 40,411 shares in the company, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 43,539 shares of company stock valued at $3,685,364 in the last three months. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW opened at $89.33 on Friday. The firm has a market capitalization of $51.44 billion, a P/E ratio of 51.34, a P/E/G ratio of 2.23 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The stock has a 50 day moving average price of $88.13 and a two-hundred day moving average price of $84.04. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the company earned $0.67 earnings per share. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on EW. Barclays restated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.